SCHEMBL1075558

SCHEMBL1075558

Cc1ccc(C(=O)c2c[nH]c3cc4c(cc3c2=O)OC(F)(F)O4)cc1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
LMNA P02545 2/20 0.50
TP53 P04637 2/20 0.50
RAB9A P51151 2/20 0.50
HSD17B10 Q99714 2/20 0.38
KDM4E B2RXH2 2/20 0.38
MEN1 O00255 2/20 0.38
HPGD P15428 2/20 0.38
KMT2A Q03164 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
NPC1 O15118 1/20 0.36
MAPT P10636 3/20 0.36
HTT P42858 1/20 0.35
GABRA1 P14867 1/20 0.34
GABRB2 P47870 1/20 0.34
POLB P06746 1/20 0.34
ATM Q13315 1/20 0.34
CYP1A2 P05177 1/20 0.34
ALOX12 P18054 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1075376 0.84 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2LMNATP53RAB9A
SCHEMBL1021286 0.84 SMN1; SMN2 (0.71) ALDH1A1SMN1; SMN2LMNATP53RAB9A
SCHEMBL1072813 0.81 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2LMNATP53RAB9A
SCHEMBL13069465 0.80 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2LMNATP53RAB9A
SCHEMBL1074470 0.78 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2LMNATP53RAB9A
SCHEMBL1075591 0.78 KDM4E (0.61) ALDH1A1LMNATP53HSD17B10KDM4E
SCHEMBL1072870 0.76 CFTR (0.54) ALDH1A1SMN1; SMN2LMNATP53RAB9A
SCHEMBL29324417 0.76 GABRA1 (0.58) ALDH1A1TP53HSD17B10KDM4EMEN1
SCHEMBL1073079 0.75 KMT2A (0.51) ALDH1A1LMNATP53HSD17B10KDM4E
SCHEMBL29254479 0.74 HSD17B10 (0.56) ALDH1A1SMN1; SMN2LMNATP53RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722311-B2 Positive resist composition and method for producing microlens NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2014-05-13 US disclosed
EP-2314590-A1 Substituted quinolones and methods of use ChemoCentryx, Inc. (US) 2011-04-27 EP disclosed
EP-2314590-A1 Substituted quinolones and methods of use ChemoCentryx, Inc. (US) 2011-04-27 EP disclosed
EP-1954274-B8 SUBSTITUTED QUINOLONES AND METHODS OF USE CHEMOCENTRYX INC (US) 2011-01-12 EP disclosed
EP-1954274-B1 SUBSTITUTED QUINOLONES AND METHODS OF USE CHEMOCENTRYX INC (US) 2010-11-03 EP disclosed
EP-1954274-B1 SUBSTITUTED QUINOLONES AND METHODS OF USE CHEMOCENTRYX INC (US) 2010-11-03 EP disclosed
US-7557213-B2 Substituted quinolones and methods of use CHEMOCENTRYX, INC. (US) 2009-07-07 US disclosed
US-7557213-B2 Substituted quinolones and methods of use CHEMOCENTRYX, INC. (US) 2009-07-07 US disclosed
US-7557213-B2 Substituted quinolones and methods of use CHEMOCENTRYX, INC. (US) 2009-07-07 US disclosed
EP-1954274-A4 SUBSTITUTED QUINOLONES AND METHODS OF USE CHEMOCENTRYX INC (US) 2009-01-07 EP disclosed
EP-1954274-A2 SUBSTITUTED QUINOLONES AND METHODS OF USE ChemoCentryx Inc (US) 2008-08-13 EP disclosed
US-20070167443-A1 Substituted quinolones and methods of use CHEMOCENTRYX, INC. (US) 2007-07-19 US disclosed
US-20070167443-A1 Substituted quinolones and methods of use CHEMOCENTRYX, INC. (US) 2007-07-19 US disclosed
US-20070167443-A1 Substituted quinolones and methods of use CHEMOCENTRYX, INC. (US) 2007-07-19 US disclosed
WO-2007059108-A2 SUBSTITUTED QUINOLONES AND METHODS OF USE CHEMOCENTRYX, INC. (US) 2007-05-24 WO disclosed
WO-2007059108-A2 SUBSTITUTED QUINOLONES AND METHODS OF USE CHEMOCENTRYX, INC. (US) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167443-A1 Substituted quinolones and methods of use TOP2A, NQO2, TOP2B ALDH1A1 1763/4885SMN1; SMN2 2712/4885LMNA 713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.